Photodynamic therapy of pterygium with verteporfin: a preliminary report.
To assess the efficacy and safety of treating pterygia by photodynamic therapy (PDT) with verteporfin (Visudyne). Ten consecutive patients with primary, recurrent, or secondary pterygium, refusing excisional surgery, were treated with a 689-nm laser delivered directly onto the pterygium after verteporfin infusion. Postoperative outcome was followed clinically and photographically for a minimum of 3 months. Successful photothrombosis of pterygium vascularization was obtained immediately after treatment in all cases. After 1 month, revascularization of pterygia was observed in 70% of cases, and treatment was repeated after a 3-month interval. Regression or stabilization of pterygia was manifested by a scarring reaction of the corneal apex with complete or partial disappearance of vascularity. No relevant side effects were observed in our series. PDT with verteporfin is a safe procedure to arrest the growth of pterygia. It is indicated for patients with a low- or medium-grade pterygium that refuse a surgical approach; however, multiple sessions may be required.